Clinical Trial Search

Primary: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline — 0.9; -1.2; -0.7; 0.7 Scores on a scale — p=0.0133

Primary: Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population — 3.069; 3.302; 3.365 Percent Change

Primary: Distribution of Visual Acuity in the Amblyopic Eye at 24 Weeks — 1; 0; 3; 0 participants

Primary: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo — 22; 40 Participants

Primary: Percentage of Participants With Complete Relief of Heartburn at Final Evaluation — 20.9; 34.4; 43.6 Percentage of participants

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8) — -7.97; -12.51; -15.28; -14.14 mmHg

Primary: Number of Subjects Who Experience Treatment Failure. — 8; 17 Participants — p=0.013

Primary: Investigator-assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 4.25; 4.08 days

Primary: Number of Participants With Treatment Emergent Adverse Events — 55; 16 participants — p=0.4228

Primary: Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population. — 21.3; 58.6; 66.5 Percentage of Participants — p=<0.0001

Primary: Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab — 2; 4 participants — p=0.685

Primary: Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP) — -13.07; -10.54; -5.84 mm Hg

Primary: Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) — 4.244; -3.187; 2.164 mL/100 mL/min — p=0.0549

Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants

Primary: HbA1c Change From Baseline to Week 24 — -0.10; -0.72 Percent — p=<0.0001